• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Arch Med Sci Atheroscler Dis . Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a s

tetano

Editor, Senior Moderator
Arch Med Sci Atheroscler Dis


. 2022 Mar 28;7:e5-e23.
doi: 10.5114/amsad.2022.115008. eCollection 2022.
Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review


Ritambhara Pandey[SUP] 1 [/SUP], Devesh Rai[SUP] 1 [/SUP], Muhammad Waqas Tahir[SUP] 1 [/SUP], Abdul Wahab[SUP] 2 [/SUP], Dhrubajyoti Bandyopadhyay[SUP] 3 [/SUP], Emil Lesho[SUP] 4 [/SUP], Maryrose Laguio-Vila[SUP] 4 [/SUP], Emilio Fentanes[SUP] 5 [/SUP], Raseen Tariq[SUP] 1 [/SUP], Srihari S Naidu[SUP] 3 [/SUP], Wilbert S Aronow[SUP] 3 [/SUP]



Affiliations

Abstract

Introduction: We performed a systematic review of comorbidities and symptoms of adult patients with coronavirus disease 2019 (COVID-19) to evaluate comorbidities, symptoms, and severity.
Material and methods: We searched databases and extracted comorbidities and symptoms from the included studies. We stratified the similar signs and symptoms in groups and on the basis of severity and compared them with stratified analysis. Individual case reports and case series with < 5 patients were excluded.
Results: A total of 163 studies with 43,187 patients were included. Mean age was 54.6 years. There were significantly fewer women in the study (43.9% vs. 56.1%, p < 0.0001). Prevalent cardiovascular comorbidities were hypertension (31.9%), obesity (27.9%), hyperlipidemia (26.4%), smoking (18.9%), diabetes mellitus (17.2%), atherosclerotic disease (9.2%) and arrhythmia (5.0%). The most frequently reported constitutional symptoms of COVID-19 were fever (73.9%), fatigue (33.4%), malaise (29.9%), myalgia and/or arthralgia (19.2%), generalized weakness (19.0%), and chills (11.3%). For the cardiovascular system, chest pain and/or tightness were most often reported (19.6%), followed by palpitations (5.2%). Hypertension and diabetes were common in severe disease. Obesity and congestive heart failure were not observed in any non-severe cases. Severe cases compared to non-severe cases more frequently had fever (87.8% vs. 58.5%, p < 0.001), shortness of breath (47.4% vs. 20.6%, p < 0.001), cough (66.8% vs. 62.9%, p < 0.001), sputum production (35.4% vs. 26.5%, p < 0.001) and rhinorrhea (32.2% vs. 7.3%, p < 0.001).
Conclusions: Hypertension, diabetes, and atherosclerotic diseases are common comorbidities across the world, with obesity as the second most common in the US and more common in men.

Keywords: COVID-19; SARS-CoV-2; comorbidities; severity; symptoms.
 
Back
Top Bottom